Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26).
- Who it may be relevant to
- Registry conditions: Idiopathic Parkinson Disease, Dyskinesias, Quality of Life. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Adaptation Of The Parkinson's Disease Dyskinesia Questionnaire Into Turkish And Its Validity And Reliability In Parkinson's Patient
Overview
The aim of this methodological study was to investigate the Turkish validity and reliability of the Parkinson's Disease Dyskinesia Scale (PDYS-26).The scale evaluates choreic dyskinesia.Measures the impact of dyskinesia on activities of daily living in patients with Parkinson's disease. Hypotheses of the Study: * Parkinson's Disease Dyskinesia Scale (PDYS-26) is reliable in Turkish. * Parkinson's Disease Dyskinesia Scale (PDYS-26) is valid in Turkish. To determine the validity of dyskinesia; * Tampa Kinesiophobia Scale, * Mini BesTest, * Activity Specific Balance Safety Scale (ABC) and * Parkinson's Disease Questionnaire-39 will be evaluated.
Detailed description
In Parkinson's disease, a neurodegenerative disorder affecting the peripheral and central nervous system, dyskinesia is a common symptom that occurs as disease processes progress and leads to disability. The term dyskinesia is a general term that covers many movement disorders. In general, it can be defined as mild to severe abnormal and involuntary muscle movements. In individuals with Parkinson's disease, it is a natural consequence of the neurodegenerative process and a motor complication of the gold standard L-dopa. Assessment of dyskinesia in Parkinson's patients is important for the implementation of appropriate medical, surgical and rehabilitation protocols. There are few scales and patient diaries that clinically assess the effect of interventions for dyskinesia. At the same time, there are deficiencies related to the reliability and validity studies of these existing scales in different languages. Therefore, limitations may arise in the assessment of dyskinesia. For this purpose, our study aims to investigate the reliability and validity of the Parkinson's Disease Dyskinesia Scale (PDYS-26) in Turkish in patients diagnosed with 130 idiopathic Parkinson's patients.In the study, the Parkinson's Disease Dyskinesia Scale (PDYS-26) will be translated into Turkish with the "back translation" method and will be finalized after the approval of the commission consisting of relevant health professionals. The final version of the scale will be applied to Parkinson's patients. To determine the validity of dyskinesia; Tampa Kinesiophobia Scale, Mini BesTest Activity Specific Balance Safety Scale (ABC) and Parkinson's Disease Questionnaire-39 will be evaluated.
Interventions
- Other Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)
The Turkish adaptation of the Parkinson's Disease Dyskinesia Scale (PDYS-26) is administered to individuals diagnosed with Parkinson's disease who have a dyskinesia score of ≥1 based on the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia item. The scale is used to evaluate dyskinesia severity and assess its clinical applicability in Turkish-speaking populations.
Primary outcome measures
- (PDYS-26) [Time frame: Baseline (Day 1) and 7 days post-baseline (Day 8)]
Eligibility criteria
Inclusion criteria
- Being diagnosed with idiopathic Parkinson's disease
- H\&Y stage 1-3
- UPDRS dyskinesia item score ≥1
- Accepting to participate in the study
Exclusion criteria
- Diagnosis of atypical-secondary parkinsonism
- Severe musculoskeletal, neurological and/or cardiopulmonary problems that may affect the results of the assessment
- Mini Mental State Examination score < 24
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Turkey (Türkiye) · 2 centers
- Bakirçay University Çiğli Regional Education Hospital — Izmir
- Izmir Bakırçay Univercity — Izmir
Publications
- Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ, Hobart J. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology. 2007 Aug 7;69(6):555-63. doi: 10.1212/01.wnl.0000266669.18308.af. PMID 17679674
Identifiers
NCT: NCT07023224 · IZBU-FTR-ITB-01